Vimarsana
Biggest News Aggregation in the World

Dipti Amin News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Dipti Amin. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Dipti Amin Today - Breaking & Trending Today

Lineage Cell Therapeutics : NOTICE OF ANNUAL MEETING OF SHAREHOLDERS TO BE HELD ON JUNE 11, 2024, PROXY - Vimarsana News

Lineage Cell Therapeutics : NOTICE OF ANNUAL MEETING OF SHAREHOLDERS TO BE HELD ON JUNE 11, 2024, PROXY

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 Schedule 14A Information ...

Lineage Cell Therapeutics : Results of Annual Meeting was held on September 6, 2023 -Today at 03:01 am - Vimarsana News

Lineage Cell Therapeutics : Results of Annual Meeting was held on September 6, 2023 -Today at 03:01 am

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT ...

Lineage Cell Therapeutics, Inc. Forecasted to Earn FY2023 Earnings of ($0.29) Per Share (NYSEAMERICAN:LCTX) - Vimarsana News

Lineage Cell Therapeutics, Inc. Forecasted to Earn FY2023 Earnings of ($0.29) Per Share (NYSEAMERICAN:LCTX)

Lineage Cell Therapeutics, Inc. (NYSEAMERICAN:LCTX – Get Rating) – Research analysts at Cantor Fitzgerald issued their FY2023 earnings per share estimates for Lineage Cell Therapeutics in a report issued on Monday, June 6th. Cantor Fitzgerald analyst K. Kluska anticipates that the company will post earnings per share of ($0.29) for the year. Lineage Cell Therapeutics […]

Brokerages Set Lineage Cell Therapeutics, Inc. (NYSEAMERICAN:LCTX) Price Target at $6.50 - Vimarsana News

Brokerages Set Lineage Cell Therapeutics, Inc. (NYSEAMERICAN:LCTX) Price Target at $6.50

Shares of Lineage Cell Therapeutics, Inc. (NYSEAMERICAN:LCTX – Get Rating) have been assigned an average rating of “Buy” from the six analysts that are currently covering the firm, MarketBeat Ratings reports. One research analyst has rated the stock with a hold rating and four have given a buy rating to the company. The average twelve-month […]

Lineage Cell Therapeutics, Inc. (NYSEAMERICAN:LCTX) Director Dipti Amin Buys 35,000 Shares - Vimarsana News

Lineage Cell Therapeutics, Inc. (NYSEAMERICAN:LCTX) Director Dipti Amin Buys 35,000 Shares

Lineage Cell Therapeutics, Inc. (NYSEAMERICAN:LCTX – Get Rating) Director Dipti Amin purchased 35,000 shares of the company’s stock in a transaction on Monday, March 28th. The stock was bought at an average price of $1.63 per share, for a total transaction of $57,050.00. The purchase was disclosed in a filing with the Securities & Exchange […]